Changeflow GovPing Healthcare & Life Sciences Faecalibacterium Butyricigenerans Patent EP3498...
Routine Notice Added Final

Faecalibacterium Butyricigenerans Patent EP3498819A1, BGI Shenzhen

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3498819A1, filed by BGI Shenzhen, covering Faecalibacterium Butyricigenerans and its method of cultivation. The application, filed by six named inventors, covers the bacterial strain and its therapeutic and pharmaceutical applications as classified under IPC C12N, A61K, and A61P. The patent designates all EU member states along with Switzerland, the UK, Norway, Turkey, and other European countries.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO published European patent application EP3498819A1 for BGI Shenzhen, covering the bacterial strain Faecalibacterium Butyricigenerans, its cultivation method, and applications in pharmaceuticals and therapeutics. The application names six inventors and is classified under IPC codes C12N 1/20, A61K 35/74, A61P 1/00, and C12R 1/01.

Biotechnology and pharmaceutical companies working with gut microbiome organisms should review this patent to assess freedom-to-operate implications for any overlapping R&D or commercial programmes involving Faecalibacterium species.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

FAECALIBACTERIUM BUTYRICIGENERANS AND METHOD FOR CULTIVATION THEREOF AND APPLICATION THEREOF

Publication EP3498819A1 Kind: A1 Apr 15, 2026

Applicants

BGI Shenzhen

Inventors

ZOU, Yuanqiang, XUE, Wenbin, XIAO, Liang, LI, Xiaoping, YU, Jinghong, LIU, Chuan

IPC Classifications

C12N 1/20 20060101AFI20200226BHEP A61K 35/74 20150101ALI20200226BHEP A61P 1/00 20060101ALI20200226BHEP C12R 1/01 20060101ALN20200226BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

C12N 1/20 A61K 35/74 A61P 1/00 C12R 1/01

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3498819A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent publication Biotech manufacturing Pharmaceutical R&D
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!